CAN_420 |
origin: |
Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. |
author: |
Zhou, X., Weeks, S.D., Ameloot, P., Callewaert, N., Strelkov, S.V., Declerck, P.J. |
patent: |
no |
patent_application_number: |
null |
CDR1_seq: |
null |
CDR1_length: |
|
CDR2_seq: |
null |
CDR2_length: |
|
CDR3_seq: |
null |
CDR3_lentgh: |
|
protein_seq: |
QVQLQESGGGLVQPGGSLRLSCAASGSIFSGNAMGWYRQAPGKQRELVAAITSGGSTDYADSVKGRFTISRDNAKNTVYL
QMNSLKPEDTAVYYCHVDPRPWGYDVTDYDYWGQGTQVTVSSHHHHHH
|
DNA_seq: |
null |
PubMed_ID: |
27279497 |
PDB_ID: |
5HVG |
PDB_deposition_date: |
2015-08-26 |
PDB_released_date: |
2016-01-27 |
resolution: |
3.05Ã… |
source_organism: |
Vicugna pacos |
experiment_method: |
null |
antigen: |
Thrombin-activatable fibrinolysis inhibitor (TAFI) |
antigen_chain: |
null |
antigen_seq: |
null |
function: |
profibrinolytic therapeutics |
validationORprediction: |
Experimentally Validated |
epitope: |
null |
bacteria_family: |
null |
publication: |
J Thromb Haemost. 2016 Aug;14(8):1629-38. doi: 10.1111/jth.13381. Epub 2016 Jul 27 |